Strain ultrasonic elastography imaging features of locally advanced breast cancer: association with response to neoadjuvant chemotherapy and recurrence-free survival

被引:3
|
作者
Wan, Caifeng [1 ,2 ]
Zhou, Liheng [1 ]
Jin, Ye [2 ]
Li, Fenghua [2 ]
Wang, Lin [2 ]
Yin, Wenjin [1 ]
Wang, Yaohui [1 ]
Li, Hongli [2 ]
Jiang, Lixin [2 ]
Lu, Jinsong [1 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Breast Surg, Pujian Rd, Shanghai 200127, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Ultrasound, Pujian Rd, Shanghai 200127, Peoples R China
基金
中国国家自然科学基金;
关键词
Neoadjuvant chemotherapy; Locally advanced breast cancer; Strain elastography; Strain ratio; Recurrence-free survival; SHEAR-WAVE ELASTOGRAPHY; PATHOLOGICAL COMPLETE RESPONSE; NODE METASTASES; WOMEN; US; STIFFNESS; MASSES;
D O I
10.1186/s12880-023-01168-2
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background Due to the highly heterogeneity of the breast cancer, it would be desirable to obtain a non-invasive method to early predict the treatment response and survival outcome of the locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NAC). This study aimed at investigating whether strain elastography (SE) can early predict the pathologic complete response (pCR) and recurrence-free survival (RFS) in LABC patients receiving NAC.Methods In this single-center retrospective study, 122 consecutive women with LABC who underwent SE examination pre-NAC and after one and two cycles of NAC enrolled in the SHPD001(NCT02199418) and SHPD002 (NCT02221999) trials between January 2014 and August 2017 were included. The SE parameters (Elasticity score, ES; Strain ratio, SR; Hardness percentage, HP, and Area ratio, AR) before and during NAC were assessed. The relative changes in SE parameters after one and two cycles of NAC were describe as Delta A1 and Delta A2, respectively. Logistic regression analysis and Cox proportional hazards model were used to identify independent variables associated with pCR and RFS.Results Forty-nine (40.2%) of the 122 patients experienced pCR. After 2 cycles of NAC, SR2 (odds ratio [OR], 1.502; P = 0.003) and Delta SR2 (OR, 0.013; P = 0.015) were independently associated with pCR, and the area under the receiver operating characteristic curve for the combination of them to predict pCR was 0.855 (95%CI: 0.779, 0.912). Eighteen (14.8%) recurrences developed at a median follow-up of 60.7 months. A higher clinical T stage (hazard ratio [HR] = 4.165; P = 0.005.), a higher SR (HR = 1.114; P = 0.002.) and AR (HR = 1.064; P < 0.001.) values at pre-NAC SE imaging were independently associated with poorer RFS.Conclusion SE imaging features have the potential to early predict pCR and RFS in LABC patients undergoing NAC, and then may offer valuable predictive information to guide personalized treatment.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Predictors for response to chemotherapy and survival in locally advanced breast cancer
    Pinto, A.
    Redondo, A.
    Zamora, P.
    Castelo, B.
    Espinosa, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer
    Choi, Moon Ki
    Park, Yeon Hee
    Kil, Won Ho
    Lee, Jeong Eon
    Nam, Seok Jin
    Ahn, Jin Seok
    Im, Young-Hyuck
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (03) : 521 - 529
  • [33] Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer
    Moon Ki Choi
    Yeon Hee Park
    Won Ho Kil
    Jeong Eon Lee
    Seok Jin Nam
    Jin Seok Ahn
    Young-Hyuck Im
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 521 - 529
  • [34] DCE-MRI derived imaging features for characterizing invasive lobular breast cancer and predicting recurrence-free survival after neoadjuvant therapy
    Tran, Geraldine
    Jones, Ella
    Li, Wen
    Fahrner-Scott, Kelly
    Newitt, David
    Joe, Bonnie
    Esserman, Laura
    Hylton, Nola
    Mukhtar, Rita
    CANCER RESEARCH, 2021, 81 (04)
  • [35] Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal
    Moog, Sophie
    Castinetti, Frederic
    DoCao, Christine
    Amar, Laurence
    Hadoux, Julien
    Lussey-Lepoutre, Charlotte
    Borson-Chazot, Francoise
    Vezzosi, Delphine
    Drui, Delphine
    Laboureau, Sandrine
    Sanson, Marie-Laure Raffin
    Lamartina, Livia
    Pierre, Peggy
    Ligner, Marie Batisse
    Hescot, Segolene
    Al Ghuzlan, Abir
    Renaudin, Karine
    Libe, Rosella
    Laroche, Suzanne
    Deniziaut, Gabrielle
    Gimenez-Roqueplo, Anne-Paule
    Jannin, Arnaud
    Leboulleux, Sophie
    Guerin, Carole
    Faron, Matthieu
    Baudin, Eric
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (09): : 2726 - 2737
  • [36] Strain wave elastography in response assessment to neo-adjuvant chemotherapy in patients with locally advanced breast cancer
    Katyan, Amit
    Mittal, Mahesh Kumar
    Mani, Chinta
    Mandal, Ashish Kumar
    BRITISH JOURNAL OF RADIOLOGY, 2019, 92 (1099):
  • [37] Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy
    Chou, Hsu-Huan
    Kuo, Wen-Ling
    Yu, Chi-Chang
    Tsai, Hsiu-Pei
    Shen, Shih-Cheh
    Chu, Chia-Hui
    Yu, Ming-Chin
    Lo, Yung-Feng
    Dabora, Muawiya A.
    Chang, Hsien-Kun
    Lin, Yung-Chang
    Ueng, Shir-Hwa
    Chen, Shin-Cheh
    BIOMEDICAL JOURNAL, 2019, 42 (01) : 66 - 74
  • [38] Optimized Breast MRI Functional Tumor Volume as a Biomarker of Recurrence-Free Survival Following Neoadjuvant Chemotherapy
    Jafri, Nazia F.
    Newitt, David C.
    Kornak, John
    Esserman, Laura J.
    Joe, Bonnie N.
    Hylton, Nola M.
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2014, 40 (02) : 476 - 482
  • [39] Neoadjuvant chemotherapy in locally advanced breast cancer.
    Soraya, Sami Sahnoun
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] Pathologic chemotherapy response score (pCRS) after neoadjuvant chemotherapy in advanced ovarian/peritoneal/fallopian tube cancer does not predict optimal cytoreduction or recurrence-free survival
    Cosgrove, C. M.
    Owda, R.
    Chen, W.
    Cohen, D.
    Cohn, D. E.
    Suarez, A. A.
    Salani, R.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 173 - 173